Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1991 May;54(5):435–439. doi: 10.1136/jnnp.54.5.435

Vigabatrin and psychosis.

J W Sander 1, Y M Hart 1, M R Trimble 1, S D Shorvon 1
PMCID: PMC488544  PMID: 1865207

Abstract

We report a series of 14 cases of psychosis occurring in patients with severe intractable epilepsy, following the prescription of vigabatrin, a new antiepileptic drug. Nine patients had no previous history of psychosis. In eight patients the psychosis occurred following a change in the habitual pattern of seizure activity; in four it developed after a period of seizure freedom followed by a cluster of seizures, and in the other four patients an alternating psychosis was observed. In five patients there was no clear relationship to seizure pattern. Another patient developed psychosis after taking an overdose of between eight and 12 g of vigabatrin. A further three patients, who developed psychosis following vigabatrin withdrawal, were not included in this series. The mean dose at onset of the psychosis (excluding the patient who took an overdose) was 2580 mg, and the period from initiation of therapy to the onset of psychosis varied from five days to 32 weeks (and occurred 24 hours after the overdose of vigabatrin). In all cases the psychosis resolved, but necessitated the withdrawal of vigabatrin, except in the single patient who took the overdose. The mechanism of this behaviour change is unclear, but in some instances may reflect vigabatrin's powerful anti-epileptic action. This is clearly not the case for all patients. Vigabatrin should be started with caution in patients with severe epilepsy, particularly in the presence of a previous history of psychosis, and such patients should be carefully monitored.

Full text

PDF
435

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ben-Menachem E., Persson L., Mumford J. Long-term evaluation of once daily vigabatrin in drug-resistant partial epilepsy. Epilepsy Res. 1990 Apr;5(3):240–246. doi: 10.1016/0920-1211(90)90045-w. [DOI] [PubMed] [Google Scholar]
  2. Butler W. H., Ford G. P., Newberne J. W. A study of the effects of vigabatrin on the central nervous system and retina of Sprague Dawley and Lister-Hooded rats. Toxicol Pathol. 1987;15(2):143–148. doi: 10.1177/019262338701500203. [DOI] [PubMed] [Google Scholar]
  3. Cross A. J., Crow T. J., Owen F. Gamma-aminobutyric acid in the brain in schizophrenia. Lancet. 1979 Mar 10;1(8115):560–561. doi: 10.1016/s0140-6736(79)90991-7. [DOI] [PubMed] [Google Scholar]
  4. GIBBS F. A. Ictal and non-ictal psychiatric disorders in temporal lobe epilepsy. J Nerv Ment Dis. 1951 Jun;113(6):522–528. [PubMed] [Google Scholar]
  5. Gram L., Klosterskov P., Dam M. gamma-Vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol. 1985 Mar;17(3):262–266. doi: 10.1002/ana.410170307. [DOI] [PubMed] [Google Scholar]
  6. Gram L., Larsson O. M., Johnsen A., Schousboe A. Experimental studies of the influence of vigabatrin on the GABA system. Br J Clin Pharmacol. 1989;27 (Suppl 1):13S–17S. doi: 10.1111/j.1365-2125.1989.tb03455.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jung M. J., Lippert B., Metcalf B. W., Böhlen P., Schechter P. J. gamma-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem. 1977 Nov;29(5):797–802. doi: 10.1111/j.1471-4159.1977.tb10721.x. [DOI] [PubMed] [Google Scholar]
  8. LEVIN S. Epileptic clouded states; a review of 52 cases. J Nerv Ment Dis. 1952 Sep;116(3):215–225. doi: 10.1097/00005053-195209000-00004. [DOI] [PubMed] [Google Scholar]
  9. Loiseau P., Hardenberg J. P., Pestre M., Guyot M., Schechter P. J., Tell G. P. Double-blind, placebo-controlled study of vigabatrin (gamma-vinyl GABA) in drug-resistant epilepsy. Epilepsia. 1986 Mar-Apr;27(2):115–120. doi: 10.1111/j.1528-1157.1986.tb03512.x. [DOI] [PubMed] [Google Scholar]
  10. Luna D., Dulac O., Pajot N., Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single-blind placebo-controlled study. Epilepsia. 1989 Jul-Aug;30(4):430–437. doi: 10.1111/j.1528-1157.1989.tb05322.x. [DOI] [PubMed] [Google Scholar]
  11. Menachem E. B., Persson L. I., Schechter P. J., Haegele K. D., Huebert N., Hardenberg J., Dahlgren L., Mumford J. P. Effects of single doses of vigabatrin on CSF concentrations of GABA, homocarnosine, homovanillic acid and 5-hydroxyindoleacetic acid in patients with complex partial epilepsy. Epilepsy Res. 1988 Mar-Apr;2(2):96–101. doi: 10.1016/0920-1211(88)90025-3. [DOI] [PubMed] [Google Scholar]
  12. Pakalnis A., Drake M. E., Jr, John K., Kellum J. B. Forced normalization. Acute psychosis after seizure control in seven patients. Arch Neurol. 1987 Mar;44(3):289–292. doi: 10.1001/archneur.1987.00520150039018. [DOI] [PubMed] [Google Scholar]
  13. Pedersen B., Højgaard K., Dam M. Vigabatrin: no microvacuoles in a human brain. Epilepsy Res. 1987 Jan;1(1):74–76. doi: 10.1016/0920-1211(87)90054-4. [DOI] [PubMed] [Google Scholar]
  14. Rimmer E. M., Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet. 1984 Jan 28;1(8370):189–190. doi: 10.1016/s0140-6736(84)92112-3. [DOI] [PubMed] [Google Scholar]
  15. Sander J. W., Hart Y. M. Vigabatrin and behaviour disturbances. Lancet. 1990 Jan 6;335(8680):57–57. doi: 10.1016/0140-6736(90)90190-g. [DOI] [PubMed] [Google Scholar]
  16. Sander J. W., Trevisol-Bittencourt P. C., Hart Y. M., Shorvon S. D. Evaluation of vigabatrin as an add-on drug in the management of severe epilepsy. J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):1008–1010. doi: 10.1136/jnnp.53.11.1008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Schechter P. J., Hanke N. F., Grove J., Huebert N., Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology. 1984 Feb;34(2):182–186. doi: 10.1212/wnl.34.2.182. [DOI] [PubMed] [Google Scholar]
  18. TELLENBACH H. EPILEPSIE ALS ANFALLSLEIDEN UND ALS PSYCHOSE. UBER ALTERNATIVE PSYCHOSEN PARANOIDER PRAEGUNG BEI "FORCIERTER NORMALISIERUNG" (LANDOLT) DES ELEKTROENCEPHALOGRAMMS EPILEPTISCHER. Nervenarzt. 1965 May;36:190–202. [PubMed] [Google Scholar]
  19. Tartara A., Manni R., Galimberti C. A., Hardenberg J., Orwin J., Perucca E. Vigabatrin in the treatment of epilepsy: a double-blind, placebo-controlled study. Epilepsia. 1986 Nov-Dec;27(6):717–723. doi: 10.1111/j.1528-1157.1986.tb03600.x. [DOI] [PubMed] [Google Scholar]
  20. Tassinari C. A., Michelucci R., Ambrosetto G., Salvi F. Double-blind study of vigabatrin in the treatment of drug-resistant epilepsy. Arch Neurol. 1987 Sep;44(9):907–910. doi: 10.1001/archneur.1987.00520210009010. [DOI] [PubMed] [Google Scholar]
  21. van Kammen D. P., Sternberg D. E., Hare T. A., Waters R. N., Bunney W. E., Jr CSF levels of gamma-aminobutyric acid in schizophrenia. Low values in recently ill patients. Arch Gen Psychiatry. 1982 Jan;39(1):91–97. doi: 10.1001/archpsyc.1982.04290010065012. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES